Lung Cancer Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030

CHAPTER 1. Industry Overview of Lung Cancer Market

1.1. Definition and Scope

1.1.1. Definition of Lung Cancer

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Lung Cancer Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Lung Cancer Market By Type

1.2.3. Lung Cancer Market By Treatment

1.2.4. Lung Cancer Market By End-User

1.2.5. Lung Cancer Market By Region

CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data End-User

2.2.1. Secondary Source

2.2.2. Primary Source

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Lung Cancer Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Lung Cancer Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Regulatory Compliance

3.9. Competitive Landscape, 2021

3.9.1. Player Positioning Analysis

3.9.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Lung Cancer Market By Type

4.1. Introduction

4.2. Lung Cancer Revenue By Type

4.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By Type, 2018-2030

4.2.2. SCLC

4.2.2.1. SCLC Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

4.2.3. NSCLC

4.2.3.1. NSCLC Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 5. Lung Cancer Market By Treatment

5.1. Introduction

5.2. Lung Cancer Revenue By Treatment

5.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By Treatment, 2018-2030

5.2.2. Surgery

5.2.2.1. Surgery Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.3. Chemotherapy

5.2.3.1. Chemotherapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.4. Photodynamic Therapy (PDT)

5.2.4.1. Photodynamic Therapy (PDT) Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.5. Radiotherapy

5.2.5.1. Radiotherapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.6. Laser Therapy

5.2.6.1. Laser Therapy Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 6. Lung Cancer Market By End-User

6.1. Introduction

6.2. Lung Cancer Revenue By End-User

6.2.1. Lung Cancer Revenue (USD Billion) and Forecast, By End-User, 2018-2030

6.2.2. Hospitals & Clinics

6.2.2.1. Hospitals & Clinics Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

6.2.3. Cancer Research Centers

6.2.3.1. Cancer Research Centers Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

6.2.4. Laboratories

6.2.4.1. Laboratories Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 7. North America Lung Cancer Market By Country 

7.1. North America Lung Cancer Market Overview

7.2. U.S.

7.2.1. U.S. Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

7.2.2. U.S. Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

7.2.3. U.S. Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

7.3. Canada

7.3.1. Canada Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

7.3.2. Canada Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

7.3.3. Canada Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

7.4. North America PEST Analysis

CHAPTER 8. Europe Lung Cancer Market By Country

8.1. Europe Lung Cancer Market Overview

8.2. U.K.

8.2.1. U.K. Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

8.2.2. U.K. Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

8.2.3. U.K. Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

8.3. Germany

8.3.1. Germany Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

8.3.2. Germany Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

8.3.3. Germany Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

8.4. France

8.4.1. France Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

8.4.2. France Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

8.4.3. France Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

8.5. Spain

8.5.1. Spain Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

8.5.2. Spain Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

8.5.3. Spain Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

8.6. Rest of Europe

8.6.1. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

8.6.2. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

8.6.3. Rest of Europe Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

8.7. Europe PEST Analysis

CHAPTER 9. Asia Pacific Lung Cancer Market By Country

9.1. Asia Pacific Lung Cancer Market Overview

9.2. China

9.2.1. China Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.2.2. China Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.2.3. China Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.3. Japan

9.3.1. Japan Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.3.2. Japan Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.3.3. Japan Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.4. India

9.4.1. India Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.4.2. India Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.4.3. India Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.5. Australia

9.5.1. Australia Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.5.2. Australia Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.5.3. Australia Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.6. South Korea

9.6.1. South Korea Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.6.2. South Korea Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.6.3. South Korea Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.7. Rest of Asia-Pacific

9.7.1. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

9.7.2. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

9.7.3. Rest of Asia-Pacific Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

9.8. Asia Pacific PEST Analysis

CHAPTER 10. Latin America Lung Cancer Market By Country

10.1. Latin America Lung Cancer Market Overview

10.2. Brazil

10.2.1. Brazil Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

10.2.2. Brazil Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

10.2.3. Brazil Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

10.3. Mexico

10.3.1. Mexico Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

10.3.2. Mexico Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

10.3.3. Mexico Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

10.4. Rest of Latin America

10.4.1. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

10.4.2. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

10.4.3. Rest of Latin America Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

10.5. Latin America PEST Analysis

CHAPTER 11. Middle East & Africa Lung Cancer Market By Country 

11.1. Middle East & Africa Lung Cancer Market Overview

11.2. GCC

11.2.1. GCC Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

11.2.2. GCC Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

11.2.3. GCC Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

11.3. South Africa

11.3.1. South Africa Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

11.3.2. South Africa Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

11.3.3. South Africa Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

11.4. Rest of Middle East & Africa

11.4.1. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By Type, 2018-2030

11.4.2. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By Treatment, 2018-2030

11.4.3. Rest of Middle East & Africa Lung Cancer Revenue (USD Billion) and Forecast By End-User, 2018-2030

11.5. Middle East & Africa PEST Analysis

CHAPTER 12. Player Analysis Of Lung Cancer Market

12.1. Lung Cancer Market Company Share Analysis

12.2. Competition Matrix

12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

12.2.2. New Product Launches and Product Enhancements

12.2.3. Mergers And Acquisition In Global Lung Cancer Market

12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 13. Company Profile

13.1. AstraZeneca plc

13.1.1. Company Snapshot

13.1.2. Business Overview

13.1.3. Financial Overview

13.1.3.1. Revenue (USD Billion), 2021

13.1.3.2. AstraZeneca plc 2021 Lung Cancer Business Regional Distribution

13.1.4. Product/Service and Specification

13.1.5. Recent Developments & Business Strategy

13.2. Eli Lilly and Company

13.3. The Merck Group

13.4. Sanofi S.A.

13.5. Pfizer Inc.

13.6. GlaxoSmithKline

13.7. F. Hoffmann-La Roche AG

13.8. Boehringer Ingelheim GmbH